识别NTRK融合癌患者
本文综述了由于TRK抑制剂疗效及larotrectinib获FDA批准,准确识别NTRK融合驱动的癌症患者具有重要临床意义。NTRK融合见于一些罕见癌症及部分常见癌症,文章回顾了pan-TRK免疫组化、FISH和测序等检测方法的优缺点,并提出基于组织学和其他分子发现对标本进行分流的检测策略。
要点
- NTRK融合由NTRK1/2/3的激酶域与多种N端伙伴融合形成,是可靶向的致癌驱动因素。
- NTRK融合见于分泌性癌、婴儿纤维肉瘤等罕见肿瘤,也偶见于黑色素瘤、胶质瘤、甲状腺癌、肺癌和结肠癌等常见肿瘤。
- 检测方法包括pan-TRK免疫组化、FISH和测序,各有优缺点,建议基于组织学和分子发现分流标本以提高检测效率。
核心结论
- 准确高效地识别NTRK融合癌患者具有临床重要性,因TRK抑制剂治疗有效且larotrectinib已获FDA批准。
研究设计与样本
- 本文为综述,回顾了识别NTRK融合的多种检测方法及其优缺点,并提出基于组织学和分子发现的分流检测策略。
主要发现
- NTRK融合由NTRK1、NTRK2或NTRK3的激酶域与多种N端伙伴融合形成。
- NTRK融合是某些罕见癌症(如乳腺或唾液腺分泌性癌、婴儿纤维肉瘤)的特征,也偶见于黑色素瘤、胶质瘤及甲状腺、肺和结肠癌等常见癌症。
关键数值与推荐
- 检测方法包括pan-TRK免疫组化、荧光原位杂交和测序方法。
- 建议根据组织学和其他分子发现对标本进行分流,以最有效地识别携带这些可治疗致癌融合的肿瘤。
临床怎么用
- 临床中应结合肿瘤组织学类型和分子检测结果,选择合适的方法检测NTRK融合,以识别适合TRK抑制剂治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK) fusion-driven cancer. These oncogenic fusions occur when the kinase domain of NTRK1, NTRK2 or NTRK3 fuse with any of a number of N-terminal partners. NTRK fusions are characteristic of a few rare types of cancer, such as secretory carcinoma of the breast or salivary gland and infantile fibrosarcoma, but they are also infrequently seen in some common cancers, such as melanoma, glioma and carcinomas of the thyroid, lung and colon. There are multiple methods for identifying NTRK fusions, including pan-TRK immunohistochemistry, fluorescence in situ hybridisation and sequencing methods, and the advantages and drawbacks of each are reviewed here. While testing algorithms will obviously depend on availability of various testing modalities and economic considerations for each individual laboratory, we propose triaging specimens based on histology and other molecular findings to most efficiently identify tumours harbouring these treatable oncogenic fusions.
引用
- Solomon JP, Benayed R, Hechtman JF, et al. Identifying patients with NTRK fusion cancer. Ann Oncol. 2019. PMID: 31738428. doi:10.1093/annonc/mdz384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。